Reuters logo
BRIEF-Ligand enters into worldwide omniab platform license agreement with Xcella Biosciences
May 30, 2017 / 1:22 PM / 6 months ago

BRIEF-Ligand enters into worldwide omniab platform license agreement with Xcella Biosciences

May 30 (Reuters) - Ligand Pharmaceuticals Inc

* Ligand enters into worldwide omniab® platform license agreement with xcella biosciences

* Under license, xcella will be able to use omnirat, omnimouse and omniflic platforms

* Ligand Pharmaceuticals - co is eligible to receive development, regulatory milestone payments, royalties for each product incorporating an omniab antibody

* Xcella will be responsible for all costs related to the omni programs Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below